secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0001193125-24-234808
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma appoints Christopher Degnan as CFO; Don Kim resigns effectively Oct 8, 2024
--------------------------------------------------------------------------------

- Don Kim resigned as CFO, principal financial and accounting officer effective Oct 8, 2024; will provide part-time consulting through Apr 28, 2025 for $36,260.
- Kim receives 9 months base salary continuation, $217,590 lump sum (2024 target bonus), and COBRA reimbursement for 9 months.
- Christopher Degnan appointed CFO effective Oct 8; prior CFO of Galera Therapeutics and Verrica Pharmaceuticals.
- Degnan receives $500,000 annual base salary, 50% target bonus, and inducement equity: option for 74,142 shares at $13.11 and 13,450 RSUs vesting over 3 years.
- Severance terms for Degnan include 6 months base salary, pro-rata bonus, and accelerated vesting of 8.33% of equity on qualifying termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524234808/0001193125-24-234808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524234808/d838231d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-234808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer